HopeStage
Back to all studies
CompletedNCT06693609

EMP-01 safety and dose study for social anxiety

About this titleRead the official source — NCT06693609

Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.

Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

What did researchers investigate?

Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.

Who was this study for?

This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Bridgetown and 6 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 8, 2025
Recruitment status
Completed
Enrollment listed in the registry
70
Sponsor
atai Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT06693609
Official title
Show the full official title

A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants With Social Anxiety Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bridgetown · Manchester · Blackpool

4 more locations
  • Liverpool
  • Tankersley
  • Thornaby
  • Leeds

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared EMP-01 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.

Who is behind this study?

The study sponsor is atai Therapeutics, Inc.

Did this study involve medication?

Yes. The study involved medication, including EMP-01 and EMP-01 Placebo.

Who was this study for?

This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies